The FDA and Intra-Cellular Therapies have reached an agreement on the proposed content and timing of a rolling new drug application submission for lumateperone, which is indicated to treat patients with schizophrenia. Intra-Cellular expects to complete the filing by midyear.
Intra-Cellular gets positive FDA feedback on rolling NDA for schizophrenia drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.